

# UNITED STATED DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

PD

	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR			ATTORNEY DOCKET NO.
_	08/849,686	08/21/97	DEGGERDAL	<u> </u>	Α	08269/003001
Γ	JANIS K FRASER FISH & RICHARDSON 225 FRANKLIN STREET BOSTON MA 02110-2804		HM12/0106	乛		EXAMINER
					OWENS JR, H	
					ART UNIT	PAPER NUMBER
					1623	15
					DATE MAILED:	01/06/00

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

## Office Action Summary

Application No. 08/849,686

Applicant(s)

....

Deggerdal et al.

Examiner

Howard Owens

Group Art Unit 1623



Responsive to communication(s) filed on							
☐ This action is <b>FINAL</b> .							
Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.							
A shortened statutory period for response to this action is set to e is longer, from the mailing date of this communication. Failure to application to become abandoned. (35 U.S.C. § 133). Extension 37 CFR 1.136(a).	respond within the period for response will cause the						
Disposition of Claims							
	is/are pending in the application.						
Of the above, claim(s)	is/are withdrawn from consideration.						
Claim(s)							
☐ Claims							
Application Papers  See the attached Notice of Draftsperson's Patent Drawing The drawing(s) filed on is/are objected The proposed drawing correction, filed on The specification is objected to by the Examiner.	d to by the Examiner.						
☐ The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. § 119  Acknowledgement is made of a claim for foreign priority under All Some* None of the CERTIFIED copies of received.  received in Application No. (Series Code/Serial Number received in this national stage application from the Instance of the CERTIFIED copies of received in this national stage application from the Instance of the CERTIFIED copies of received in this national stage application from the Instance of the CERTIFIED copies of received in this national stage application from the Instance of the CERTIFIED copies of	the priority documents have been ber) nternational Bureau (PCT Rule 17.2(a)).						
Attachment(s)  Notice of References Cited, PTO-892 Information Disclosure Statement(s), PTO-1449, Paper Notice Interview Summary, PTO-413 Notice of Draftsperson's Patent Drawing Review, PTO-948 Notice of Informal Patent Application, PTO-152							
SEE OFFICE ACTION ON TH	HE FOLLOWING PAGES						

Serial No. 08/849,686

Art Unit 1623

Ŋ

#### Response to Arguments

The following is in response to the amendment filed 10/12/99:

An action on the merits of claims 1-24 is contained herein below.

10 Objection to the specification is maintained.

#### 35 USC 112(2) Rejection

As the instant claims have not been amended to remedy the rejection of claims 13 and 19-21 set forth in the office action dated 5/12/99, the rejection of the claims is maintained.

### 20 **35 USC 102 Rejection**

30

35

The rejection of claims 1, 2 and 14 are under 35 U.S.C. 102(b) is maintained for the reasons of record.

As noted by applicant inherency can only be established if it is recognized by persons of skill in the art that the missing descriptive matter is present in the reference.

As recited from the previous office action, the Pharmacia Catalog discloses oligo(dT) Cellulose (Product Code No. 27-5543-01) for the isolating of mRNA from a cell lysate which can certainly contain any conventional detergent. Oligo(dT) Cellulose is certainly an organic support which can bind mRNA in the presence of detergents. Furthermore, the material can be washed and the nucleic acid eluted with heat which simply denatures the double-stranded nucleic acid. One of skill in the art would clearly recognize that clearly recognize the common use of detergents within the art of purification of nucleic acids; moreover, that the Pharmacia product could be used in the absence of a

Serial No. 08/849,686

Art Unit 1623

3

20

25

30

chaotropic agent, barring evidence to the contrary, which has not been presented by applicant.

#### 35 USC 103 Rejections

The rejection of claims 1 - 24 under 35 U.S.C. 103(a) as being unpatentable over as being unpatentable over Reardon et al. (4,997,932) has been withdrawn.

Applicant's arguments filed 10/12/99 in response to the rejection of claims 1-12 and 14-18 under 35 U.S.C. 103(a) as being unpatentable over the 1994 Pharmacia Biotechnology Products Catalog., have been fully considered but they are not persuasive. The rejection of claims 1-12 and 14-18 under 35 U.S.C. 103(a)is maintained for the reasons set forth below.

Applicant's claim that the targeting of the Pharmacia product is limited to mRNA tails is countered by the inclusion of "fractionization of olignonucleotides" apart from mRNA isolation set forth in the Pharmacia catalog clearly indicating that nucleic acids are within the scope of the invention.

With regards to the reference suggesting all of the limitations specifically the presence of a detergent and in the absence of a chaotropic agent, as cited previously "The Pharmacia Catalog discloses Oligo(dT) Cellulose which is an organic support which can bind nucleic acids in the presence of a detergent, buffers, salt, and chelating agents, then elute said nucleic acid upon heating". There is no evidence that one of skill in the art could not use the claimed Pharmacia invention in the absence of chaotropic agents. One of the facets of determining obviousness

Serial No. 08/849,686

4

Art Unit 1623

is not only determining the scope and contents of the prior art, but resolving the level of ordinary skill in the pertinent art.

Given this, one of skill in the art would clearly recognize the common use of detergents within the art of purification of nucleic acids.

10 Claims 22-24 appear to be allowable.

15

20

25

30

35

40

5

10

15

ENDING

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Howard Owens whose telephone number is  $(703)\ 306-4538$ . The examiner can normally be reached on Mon.-Fri. from  $8:30\ a.m.$  to  $5\ p.m.$ 

If attempts to reach the examiner by telephone are unsuccessful, the Primary Examiner signing this action, James O. Wilson can be reached on (703) 308-4624. The fax phone number for this Group is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-1235.

Howard Owens

Group 1623

20

GARY L. KUNZ PRIMARY EXAMINER

UP 1200